The importance of protecting against respiratory disease
Respiratory diseases such as equine influenza (flu) and equine herpesvirus (rhino) are classified as risk-based by the American Association of Equine Practitioners (AAEP) because their likelihood of occurrence depends on factors like travel or cohabitation with traveling horses.2 Due to their high contagiousness, flu and rhino are the top risk-based vaccinations recommended for horses. Among risk-based diseases, respiratory disease is the primary cause of horse death, with equine flu and herpesvirus being the main respiratory illnesses.2
Equine Influenza (Flu)
Equine Herpesvirus (Rhino)
The benefits of Fluvac Innovator®
Fluvac Innovator EHV-4/1 provides trusted protection against the risks of equine influenza (flu) and herpesvirus (rhino). Plus, research has shown that dividing core and risk-based vaccines into separate injections provided up to 4.7 times the immune response against equine influenza than combination vaccines that included equine influenza protection.3
The #1 most trusted equine respiratory vaccine in the United States1
Up to 4.7x better immune response against equine influenza3
Since 2018, Fluvac Innovator has been successfully evaluated against 101 equine influenza viruses from 38 locations4-9
Oil-in-water adjuvants, such as MetaStim®, were shown to promote cross-protective immunity against influenza strains in both humans and animals.10
Choose Fluvac Innovator® EHV-4/1 with confidence
When should I vaccinate my horse?
By splitting core from risk-based vaccines, your horse gets a customized vaccination program to help protect against the diseases that are most likely to be a threat. Learn more about vaccinating your horse for the five core equine diseases with Core EQ Innovator. Below is a vaccination schedule for protection from the core diseases and risk-based respiratory diseases aligned to the AAEP guidelines.2
What sets Zoetis Innovator vaccines apart?
MetaStim® adjuvant
Only Zoetis Innovator vaccines are optimized with the MetaStim® adjuvant, designed to make presenting antigens into your horse’s immune system safe and effective, leading to an improved immune response.13,14
Microfiltered 5x
Zoetis Innovator vaccines are microfiltered five times to remove excess proteins that could lead to increased reactivity, resulting in greater antigen purity.
Zoetis Vaccine Support Program
When you protect your horse with Core EQ Innovator and Fluvac Innovator EHV-4/1 vaccines, you are also protected with one of the industry’s best Equine Immunization Support Guarantees. This reimburses up to $5,000 for documented diagnostic and treatment costs if a veterinarian properly administers one of these vaccines and the horse later contracts the corresponding disease. For complete details and requirements, see the see the Zoetis Equine Immunization Support Guarantee certificate.
We would love to hear your Fluvac Innovator® success story
Protecting against respiratory disease
References
- The Fluvac Innovator line had the most doses sold of all equine influenza vaccine lines on the market. Animalytix Segment Data, Equine Vaccines, MAT June 2023 (accessed June 20, 2023).
- American Association of Equine Practitioners. Vaccination Guidelines. https://aaep.org/guidelines/vaccination-guidelines. (Accessed January 22, 2023.)
- Data on file, Study Report No. 14OREQBIO-1, Zoetis Inc. Data on file, Study Report No. 18EQRGBIO-01-02, Zoetis Inc.
- Data on file, Study Report No. 18EQRGBIO-01-02, Zoetis Inc.
- Dilai M, et all. Serological investigation of racehorse vaccination against equine influenza in Morocco. Veterinary Microbiology. 223. 2018. 153-159.
- Data on file, Study Report No. 19EQRGBIO-01-02, Zoetis Inc.
- Data on file, Study Report No. 21EQRGBIO-01-01, Zoetis Inc.
- Data on file, Study Report No. 22EQRGBIO-01-01, Zoetis Inc.
- Data on file, Study Report No. 23EQRGBIO-01-01, Zoetis Inc.
- Vemula SV, Sayedahmed EE, Sambhara S, Mittal SK. Vaccine approaches conferring cross-protection against influenza viruses. Expert Rev Vaccines. 2017;16(11): 1141–1154.
- Landolt G, Hugh G, Townsend G, Lunn D. Equine influenza infection. In: Sellon D, Long M, eds. Equine Infectious Diseases, 1st edition. Philadelphia: WB Saunders, 2007;127.
- Data on file. Study Report No. B951R-US-20-160, Zoetis Inc.
- Davis EG, Zhang Y, Tuttle J, Hankins K, Wilkerson M. Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine. Vet Immunol Immunopathol. 2008;126(3-4):293-301.
- Horohov DW, Dunham J, Liu C, et al. Characterization of the in situ immunological responses to vaccine adjuvants. Vet Immunol Immunopathol. 2015;164(1-2):24-29.
- Data on file. Study Report No. B951R-US-20-160, Zoetis Inc.
- Epp T, Waldner C, Townsend HGG. A case-control study of factors associated with development of clinical disease due to West Nile virus, Saskatchewan 2003. Equine Vet J. 2007;39:498-503
- Bryans JT, Allen GP. Application of a chemically inactivated, adjuvanted vaccine to control abortigenic infection of mares by equine herpesvirus 1. Dev Biol Stand. 1982;52:493-498.
- Tengelsen LA, Yamini B, Mullaney TP, et al. A 12-year retrospective study of equine abortion in Michigan. J Vet Diagn Invest. 1997;9(3):303-306.
- Giles RC, Donahue JM, Hong CB, et al. Causes of abortion, stillbirth, and perinatal death in horses: 3,527 cases (1986-1991). J Am Vet Med Assoc. 1993;203(8):1170-1175.
- Hong CB, Donahue JM, Giles RC, et al. Equine abortion and stillbirth in central Kentucky during 1988 and 1989 foaling seasons.
- J Vet Diagn Invest. 1993;5(4):560-566.
FLU-00178